Lateral in Biological Technology

Atomic force microscopy reveals liquids adjust viscosity when confined, shaken

... immersed in water or silicon oil, while small lateral oscillations were applied to the cantilever ... of confined fluids from direct high-resolution lateral force measurements. The normal and lateral forces acting on the tip were measured directly ...

VerteLoc™ Tops 500 Surgical Procedures, VGI Announces VerteLX™ and Seeks Potential Investors for Growth

... / devices on the market that are inserted from an anterior, posterior or lateral surgical approach," Grayson elaborated. "Many current systems, ... will introduce a system that utilizes just a few small instruments for the lateral surgical approach and insertion of a unique biomechanically superior ...

Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th

... Corey will attend both baseball games to raise awareness of amyotrophic lateral scleroses (ALS, Lou Gehrig's disease) a neurodegenerative disease of which ... TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible. Focused on ...

Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States

... designed to increase the awareness and understanding of ALS (amyotrophic lateral sclerosis), otherwise known as Lou Gehrig's disease. To accomplish its ... TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible. Focused on ...

ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer

... development effort in the world focused entirely on stopping amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). ALS is a progressive ... TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) as soon as possible. Focused on ...

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)

... will continue to be responsible for the IPLEX(TM) EAP for Amyotrophic lateral Sclerosis (ALS) in Italy, as well as all IPLEX(TM)-related activities in ... that are suffering from debilitating diseases, such as Amyotrophic lateral Sclerosis, and have no other medical options," said Dr. Geoffrey Allan, ...

Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results

... clinical development programs in diabetic neuropathy (DN) and amyotrophic lateral sclerosis (ALS) and pre-IND programs to develop ZFP Therapeutics for the ... Initiation of Phase 2 clinical trial (SB-509-801) of SB-509 in amyotrophic lateral sclerosis (ALS). In September, Sangamo initiated a Phase 2 clinical trial ...

ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology

... in the professional marketplace for certain technologies pertaining to lateral flow immunoassay devices and methods. This license agreement provides ... line now in development will extend these attributes into rapid test lateral flow devices and maintain Abaxis' standards of product excellence," said ...

Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast

... go from known to unknown, so unlike many robotic surgeons, who work from lateral to medial and may be surprised by a big median lobe, I like to see exactly ... fundamental belief to which he adheres. "I try to stay away from the lateral tissues as much as possible, because that's where you have most of your ...

A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders

... neuropathic pain. Ten adult patients diagnosed with chronic neuropathic pain successfully underwent non-invasive deep brain ablation surgery (central lateral thalamotomy) with transcranial MRgFUS and showed improvement in pain scores and reduction of pain medication with no adverse effects at three months ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

... and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iPierian has a collaboration with The Gladstone Institute of ...

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

... continues to demonstrate a strong safety profile and we believe it offers a potential treatment in multiple therapeutic areas, including Amyotrophic lateral Sclerosis. Beyond IPLEX(TM), our current cash reserves of approximately $120 million provides us with a significant opportunity to continue growing ...

A*STAR scientists invent the world's only controllable molecule gear of minuscule size of 1.2nm

... breakthrough because before the team's discovery, motions of molecular rotors and gears were random and typically consisted of a mix of rotation and lateral displacement. The scientists at IMRE solved this scientific conundrum by proving that the rotation of the molecule-gear could be wellcontrolled by ...

iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board

... will look to Dr. Goodman's extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular atrophy and Parkinson's disease," said John P. Walker, chief executive officer of iZumi. "Over the next few months, we ...

Insmed Announces First Quarter 2009 Financial Results

... of 2009; The FDA announced that it would allow Insmed to provide access to IPLEX(TM) for investigational use in patients with Amyotrophic lateral Sclerosis (ALS or Lou Gehrig's disease). Insmed will conduct a controlled clinical trial under an Investigational New Drug application; ...

iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development

... and Highland Capital Partners. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iZumi has a collaboration with The Gladstone Institute of ...

Neogen Develops Quickest Single Test for Beta-Lactams and Tetracyclines in Milk

... European Union's maximum residue levels, Neogen's new BetaStar(R) Combo utilizes the same format as the popular BetaStar assay -- an extremely easy lateral flow test that requires only minimal training and equipment to produce consistently accurate results. At just 5 minutes, BetaStar Combo is the ...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.

... this therapeutic platform is a spinal cord cell line. When implanted into animal models, the cells have extended the lives of rats with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and reversed paralysis in ischemic spastic paraplegia models. In December 2008, Neuralstem filed an ...

GYNECARE PROLIFT+M(TM) Pelvic Floor Repair System Launched in US for Use in Pelvic Organ Prolapse Surgery

... help the surgeon place the mesh more easily because it resists wrinkling and folding, and it has increased longitudinal elasticity while maintaining lateral support to ensure pliability after surgery. The new design may improve vaginal wall compliance and allow for better tissue incorporation. ...

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

... and $1.4 billion; Generated $10.5 million in cost recovery revenue from the IPLEX(TM) expanded access program (EAP) for Amyotrophic lateral Sclerosis (ALS or Lou Gehrig's disease) in Italy during 2008. The EAP now includes 110 patients enrolled and 23 physicians; Gained ...

Seminar Will Bring ALS Researchers to Patient Groups

... to inform and update patients, their families and local communities on worldwide efforts to discover and develop effective treatments for amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). People diagnosed with this fatal disease typically succumb within three years of initial symptoms because ...

Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference

... with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has ...

Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent

... with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has ...

Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference

... program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and amyotrophic lateral sclerosis (ALS). Other therapeutic development programs are focused on HIV/AIDS, cancer, neuropathic pain, nerve regeneration, Parkinson's disease ...

Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes

... of age and above. The efficacy of BOTOX(R) treatment in deviations over 50 prism diopters, in restrictive strabismus, in Duane's syndrome with lateral rectus weakness, and in secondary strabismus caused by prior surgical over-recession of the antagonist has not been established. BOTOX(R) is ...

NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists

... the conference: Tuesday, November 18, 1:00 PM - 5:00 PM -- In-vitro Skin Permeation of Novel Antimicrobial Nanoemulsion Formulations -- lateral Diffusion of a Novel Antifungal Nanoemulsion In-vitro Human Cadaver Skin -- Pharmacokinetics of a Novel Topical Antimicrobial Nanoemulsion ...

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

... quarter related to the expanded access program ("EAP") for IPLEX(TM). The EAP in Italy to treat patients with Amyotrophic lateral Sclerosis ("ALS"), also known as Lou Gehrig's Disease, currently includes 23 physicians and over 100 subjects have enrolled; ...

DynaVox Releases Software Version 1.05 for DynaVox V and Vmax

... of adults and children around the world challenged by significant speech, language and learning disabilities caused by conditions such as amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease), stroke, traumatic brain injury, cerebral palsy, Parkinson's Disease, autism and mental retardation. Driving ...

Sangamo BioSciences Reports Third Quarter 2008 Financial Results

... supply expenses. Recent Highlights * Initiation of a Phase 2 clinical trial (SB-509-801) to evaluate SB-509 in subjects with Amyotrophic lateral Sclerosis (ALS). ALS is a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure. The ...

Nuvasive Reports Third Quarter 2008 Financial Results

... market share. At NASS we unveiled NeuroVision M5, which represents a significant upgrade to our core MAS platform, further distancing our innovative lateral approach from the competition and providing our surgeon customers with an even more intuitive and user friendly system." Mr. Lukianov concluded, ...

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

... of IPLEX(TM) in potentially treating some of the most under-served therapeutic populations, including Myotonic Muscular Dystrophy and Amyotrophic lateral Sclerosis." Clinical Study Results Low levels of IGF-I are known to contribute to the pathogenesis of ROP. The objectives of this open label, ...

Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit

... Md., Sept. 8 /PRNewswire-FirstCall/ -- Neuralstem Inc., CEO, Richard Garr, will be a featured panelist discussing stem cells and ALS (Amyotrophic lateral Sclerosis, or Lou Gehrig's disease) at the 2008 World Stem Cell Summit in Madison, Wisconsin, on September 22, at 2:00 CDT. In a presentation prior ...

Neuralstem Reports Second Quarter Financial Results and Highlights

... be working with Dr. Karl Johe, Neuralstem's Chairman and Chief Science Officer, to manage the Company's upcoming clinical trial for ALS (Amytrophic lateral Sclerosis, or Lou Gehrig's disease), and complete development of Neuralstem's small molecule neurogenesis compound targeted to treat depression. ...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

... the second quarter related to the expanded access program ("EAP") for IPLEX(TM). The EAP in Italy to treat patients with Amyotrophic lateral Sclerosis ("ALS"), also known as Lou Gehrig's Disease, currently includes 22 physicians and approximately 100 subjects have enrolled. ...

iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits

... demonstrates that iPS cells derived from an individual patient can be differentiated into motor neurons, the cell type affected in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Large-scale, standardized production of such iPS-derived cells could be used for a variety of ...

Penn scientists carve functional nanoribbons using super-heated, nano-sized particles of iron

... investigated the construction of atomically precise graphene nanoribbons in which charge-carrying electrons are confined in a nearly two-dimensional, lateral plane and the electronic properties of the ribbon are controlled by the width and specific crystallographic orientation of the material. These ...

Neuralstem Fills Key Product Development Position

... be working with Dr. Karl Johe, Neuralstem's Chairman and Chief Science Officer, to manage the company's upcoming clinical trial for ALS (Amytrophic lateral Sclerosis, or Lou Gehrig's disease), and complete development of Neuralstem's small molecule neurogenesis compound targeted to treat depression. ...

ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration

... Stem Cell, Inc. (CSC) announced today a new collaboration aimed at advancing any potential application of stem cells in treating ALS - amyotrophic lateral sclerosis, commonly known as Lou Gehrig's diseases. The new set of experiments will begin in August 2008 and continue through the end of 2009. This ...

Repair Stem Cell Institute Announces Science Advisory Board

... conditions treatable by stem cell transplantation. He and his team are the first known in the world to treat multiple sclerosis and amyotropic lateral sclerosis patients by injecting their spinal fluid with large numbers of repair stem cells (mesenchymal stromal stem cells) taken from their bone ...

Liko Introduces Two Additions to Its 'Stat' Family of Low Friction Sheets

... . Liko's new Stat HandyTube is designed to assist caregivers in repositioning, turning patients, or performing lateral transfer maneuvers. The Stat HandyTube is offered in three sizes: short, long, and wide. The wide model features sewn-on handles to provide extra ...